Holen Sie sich die Stockscreener-App
1.40
3.45%
-0.05
Vorhandelsmarkt:
1.40
Gri Bio Inc Aktie (GRI) Neueste Nachrichten
GRI Bio Inc (GRI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
GRI Bio Inc (GRI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
GRI|GRI Bio Inc|Price:1.420|Chg%:-0.030 - TradingKey
GRI Bio Inc (GRI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
GRI Bio Inc (GRI) Income Statement - TradingKey
Gri Bio, Inc. (GRI) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
TradingKey - TradingKey
GRI Bio, Inc. Revenue Breakdown – NASDAQ:GRI - TradingView
GRI Bio Inc (GRI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
GRI Bio Inc (GRI) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Price to sales forward of GRI Bio, Inc. – NASDAQ:GRI - TradingView
CHGA Stock Price and Chart — NASDAQ:CHGA - TradingView
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
GRI Bio Inc. Q1 2026 Earnings: EPS Misses Estimates by 76%, Stock Rises 2.6% Amid Strategic Progress - Bölüm Sonu Canavarı
Price to earnings forward of GRI Bio, Inc. – NASDAQ:GRI - TradingView
GRI Q1 2026 Earnings: EPS Misses Estimates by Wide Margin, Revenue AbsentSubscription Growth Report - dars.gov.et
GRI Bio Inc. (GRI) Declines Over 8%, Approaching Critical Support at $1.73Liquidity Order Flow - dars.gov.et
GRI Q1 2026 Earnings: EPS Misses Estimates by 76%, Shares Slide 8%Mid-Term Outlook - dars.gov.et
Price to sales forward of GRI Bio, Inc. – BOATS:GRI - TradingView
Enterprise value to revenue forward of GRI Bio, Inc. – NASDAQ:GRI - TradingView
GRI Bio Inc. Q1 2026 Earnings: EPS Misses Estimates by over 76% as Pre-Revenue Biotech Continues Development - dars.gov.et
Enterprise value to EBIT forward of GRI Bio, Inc. – NASDAQ:GRI - TradingView
Price to earnings forward of GRI Bio, Inc. – BOATS:GRI - TradingView
Enterprise value to EBIT forward of GRI Bio, Inc. – BOATS:GRI - TradingView
Enterprise value to EBITDA forward of GRI Bio, Inc. – NASDAQ:GRI - TradingView
GRI Q1 2026 Earnings: EPS Miss Widens Losses as Pre-Revenue Biotech Stock RalliesProfit Margin Analysis - DonanımHaber
ADTX Stock Price and Chart — OTC:ADTX - TradingView
GRI Bio, Inc. Actuals & Estimates (NASDAQ:GRI) - TradingView
GRI Forecast — Price Target — Prediction for 2027 - TradingView
GRI Bio Inc. (GRI) Rallies 3.8% as Momentum Builds Above Key SupportBollinger Expansion - dars.gov.et
GRI Bio Inc (GRI) Institutional Confidence - TradingKey
GRI Bio Inc (GRI) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
GRI Bio Secures FDA Orphan Drug Status for IPF - TipRanks
FDA grants Orphan Drug Designation to GRI Bio (NASDAQ: GRI) therapy GRI-0621 in IPF - Stock Titan
GRI Bio receives orphan drug status for IPF treatment - Investing.com
GRI Bio receives FDA orphan drug designation for IPF treatment - grafa.com
GRI Bio receives orphan drug status for IPF treatment By Investing.com - Investing.com Canada
GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis - GlobeNewswire
GRI Bio Inc (GRI) Valuation: PE, PB & Fair Value Analysis - TradingKey
GRI Bio Inc (GRI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
GRIGRI Bio Inc Forecast, Target Price - Finviz
GRI Q1 2026 Earnings: EPS Misses Estimates by 76% Amid Revenue AbsenceEarnings Per Share - lwvtexas.org
GRI Q1 2026 Earnings: Wider-than-expected loss amid ongoing R&D investmentsEarnings Sentiment Score - dars.gov.et
GRI Bio Inc. (GRI) Slips Over 5% as Stock Tests Key Support Near $1.90Median Line - newsline.com
GRI Q1 2026 Earnings: EPS Miss by 76% as Pre-Clinical Biotech Continues to Report No RevenueWeak Earnings Momentum - newsline.com
GRI Q1 2026 Earnings: Wider-than-Expected Loss as EPS Misses EstimatesLong-Term Guidance - newsline.com
Dell Technologies To Gain Nearly 79%? Here Are 10 Analyst Calls Investors Should Know - Benzinga
GRI Q1 2026 Earnings: EPS Misses Estimates by a Wide Margin Amid Stepped-Up R&D SpendingROIC Trend Report - newsline.com
GRI Q1 2026 Earnings: Wider-than-Expected Loss as EPS Misses Estimates by 76%Dividend Increase Stocks - newsline.com
GRI Bio Inc. (GRI) Struggles Near Support Amid Mixed Technical SignalsVolume Gap - The Legal Advocate
GRI Bio Inc. (GRI) Posts Modest Gains as Stock Holds Above Key SupportWyckoff Spring - The Legal Advocate
GRI Bio Inc. Q1 2026 Earnings: EPS Misses Estimates as Development-Stage Company Faces HeadwindsEPS Consistency Score - The Legal Advocate
GRI Bio Inc. (GRI) Slides 7% as Shares Test Key Support at $1.96Relative Volume - Newser
1.97%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):